全球免疫蛋白诊断检测市场 – 行业趋势和 2030 年预测

免疫蛋白诊断测试市场分析和规模

慢性病的广泛流行增加了对免疫蛋白诊断检测的需求。根据世界卫生组织的记录，全球卫生观察站的数据显示，约有 160 万人（占总死亡人数的 2.8%）是由糖尿病引起的。随着免疫蛋白诊断技术的巨大进步，化学发光检测技术得到了迅速发展。有几种技术可以帮助快速检测慢性病，并配备全自动工具。

Data Bridge Market Research分析，免疫蛋白诊断检测市场预计到2030年将达到145.8亿美元，即2022年为83.6亿美元，预计在2023年至2030年的预测期内复合年增长率为7.2%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

免疫蛋白诊断测试市场范围和细分

Market Definition

Immunoproteins are the blood proteins which are involved in playing a major role in the functioning of the immune system. These proteins contain an immunological activity against pathogenic substances since they display an abnormal increase in blood concentration thus acting as a standard indicator in disease diagnosis during an unhealthy state. The immunoproteins form a whole body system in cells, tissues or organs which help to balance the dangerous effects of antigens.

Immunoprotein Diagnostic Testing Market Dynamics

Drivers

• Increasing Incidence of Chronic Diseases

The major reason for the growth in the demand for immunoprotein diagnostic testing services is the rise in incidence and incidence rate of chronic diseases. As per the records of WHO, the Global Health Observatory recommends that nearly 1.6 million, which is around 2.8% of the total deaths, are caused by diabetes. Furthermore, lung cancer alone was primarily responsible in 2012 to cause around 1.6 million deaths as per the statistics of WHO report. In this regard, early diagnosis and testing is necessary. This boosts the market growth.

• Rising Incidence of Non-communicable Diseases and Diabetes

As per the WHO records, the number of people having diabetes has increased from 108 million in 1980 to 422 million in 2014, indicating a huge rise in the incidence of diabetes. Furthermore, as per the Global Health Observatory data by WHO in 2017, about 70% of global deaths lead to 39.5 million are caused because of non- communicable diseases (NCD) such as cardiovascular diseases, cancers, chronic lung diseases, and diabetes. Thus, it leads to the increase in these testing patterns.

Opportunities

• Rise in Diagnostic Tests

There are several diagnostic tests that are helping in the expansion of the market growth. C-Reactive Protein (CRP) tests is widely used due to the wide product portfolio of major market players. These tests help to identify inflammation by determining the amount of CRP in the patient. It also help in observing the effectiveness of treatment for several infectious diseases and cancer. Furthermore, free light chain diagnostic tests are expected to show major growth during the forecast period. This is because of their ability to help in detection, diagnosis, and monitoring of plasma cell disorders. This testing is beneficial for patients suffering from light chain-only multiple myeloma, oligosecretory myeloma, or nonsecretory myeloma. Thus, all these tests are increasing the market growth.

• Growing Demand of Chemiluminescence assay

Chemiluminescence assay is projected to show the maximum growth during the forecast period because of its high specificity and sensitivity along with ability to identify antigens in human serum and plasma samples. Chemiluminescence assay is often characterized as a major tool for quick diagnosis of numerous diseases and is determined to be more accurate than fluorescence-based detection of labelled probes. Thus, this assay is certainly growing the market growth.

Restraints/Challenges

• High cost of Diagnostic Tests

Different tests are available for testing chronic diseases, cardiovascular and other conditions such as diabetes. But these tests are of much high cost which is not afforded by many patients, especially belonging to the lower economic groups. Thus, it hampers the market growth.

This immunoprotein diagnostic testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immunoprotein diagnostic testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Bio-Rad partnered with Seegene, which is a major market player in multiplex molecular diagnostics, used for the clinical commercialization and huge development of infectious disease diagnostic solutions
• In 2021, Roche collaborated with PathAI, which is a world leader in pathology-based AI-powered technology. The companies collaborated intending to jointly develop an embedded image analysis workflow for different pathologists

Global Immunoprotein Diagnostic Testing Market Scope

免疫蛋白诊断测试市场根据类型、应用、技术和最终用户进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

类型

• C反应蛋白诊断测试
• 补体系统蛋白诊断测试
• 前白蛋白诊断测试
• 结合珠蛋白诊断测试
• 免疫球蛋白诊断测试
• 免费轻链诊断测试
• 其他的

应用

• 自身免疫检测
• 传染病检测
• 过敏测试
• 内分泌检测
• 肿瘤学检测
• 毒理学测试
• 其他的

技术

• 放射免疫分析法
• 免疫比浊法
• 免疫蛋白电泳
• 酶联免疫吸附试验
• 其他的

终端用户

• 医院和诊所
• 诊断实验室
• 其他的

免疫蛋白诊断测试区域分析/见解

对免疫蛋白诊断测试市场进行了分析，并按类型、应用、技术和最终用户提供了市场规模洞察和趋势。

免疫蛋白诊断测试市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

北美在免疫蛋白诊断检测市场占据主导地位，因为随着诊断仪器和实验室数量的增加，癌症发病率也不断上升。此外，美国人口中癌症的高发病率也导致了该市场的巨大增长。此外，美国人口中癌症的高发病率也导致了该市场的增长。

由于美国人口中癌症和糖尿病的发病率很高，预计亚太地区将在 2023 年至 2030 年的预测期内实现最高增长率。德国政府采取的举措激增，为患有多因素和慢性疾病的人进行不同的检测，特别是检测癌症、肺癌、糖尿病和心血管疾病，这是推动该地区增长的主要因素之一。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

免疫蛋白诊断测试市场还为您提供每个国家/地区资本设备医疗支出增长、免疫蛋白诊断测试市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对免疫蛋白诊断测试市场的影响的详细市场分析。数据涵盖 2011-2020 年的历史时期。

竞争格局和全球免疫蛋白诊断测试市场份额分析

免疫蛋白诊断测试市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对免疫蛋白诊断测试市场的关注有关。

免疫蛋白诊断测试市场的一些主要参与者包括：

• 雅培（美国）
• Abcam plc（英国）
• Bio-Rad Laboratories, Inc.（美国）
• 丹纳赫（美国）
• DiaSorin SpA（意大利）
• Enzo Biochem (美国)
• Ortho Clinical Diagnostics（美国）
• 赛默飞世尔科技公司（美国）
• 生物梅里埃公司（法国）
• 安捷伦科技公司（美国）
• Enzo Life Sciences, Inc（印度）
• Randox Laboratories Ltd（英国）
• SERVA Electrophoresis GmbH（德国）
• Calbiotech（美国）
• Eurobio Scientific（法国）
• Meridian Bioscience, Inc.（美国）
• A.Menarini Diagnostics srl（意大利）
• 礼来（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• 西门子医疗有限公司（德国）

SKU-56900